Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $148.84 million. The enterprise value is $55.03 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 9.39 million shares outstanding. The number of shares has increased by 167.19% in one year.
| Current Share Class | 9.39M |
| Shares Outstanding | 9.39M |
| Shares Change (YoY) | +167.19% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 6.41% |
| Owned by Institutions (%) | 63.25% |
| Float | 4.89M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.45 |
| Forward PS | n/a |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.41, with a Debt / Equity ratio of 0.33.
| Current Ratio | 9.41 |
| Quick Ratio | 9.07 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.22% and return on invested capital (ROIC) is -32.13%.
| Return on Equity (ROE) | -60.22% |
| Return on Assets (ROA) | -29.82% |
| Return on Invested Capital (ROIC) | -32.13% |
| Return on Capital Employed (ROCE) | -50.43% |
| Revenue Per Employee | $46,356 |
| Profits Per Employee | -$840,490 |
| Employee Count | 104 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $124,000 in taxes.
| Income Tax | 124,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.84% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -65.84% |
| 50-Day Moving Average | 14.88 |
| 200-Day Moving Average | 34.49 |
| Relative Strength Index (RSI) | 56.98 |
| Average Volume (20 Days) | 203,907 |
Short Selling Information
The latest short interest is 1.07 million, so 11.39% of the outstanding shares have been sold short.
| Short Interest | 1.07M |
| Short Previous Month | 1.06M |
| Short % of Shares Out | 11.39% |
| Short % of Float | 21.89% |
| Short Ratio (days to cover) | 10.35 |
Income Statement
In the last 12 months, Korro Bio had revenue of $4.82 million and -$87.41 million in losses. Loss per share was -$9.44.
| Revenue | 4.82M |
| Gross Profit | 4.82M |
| Operating Income | -95.48M |
| Pretax Income | -81.17M |
| Net Income | -87.41M |
| EBITDA | -91.41M |
| EBIT | -95.48M |
| Loss Per Share | -$9.44 |
Full Income StatementBalance Sheet
The company has $114.95 million in cash and $45.19 million in debt, giving a net cash position of $93.81 million or $9.99 per share.
| Cash & Cash Equivalents | 114.95M |
| Total Debt | 45.19M |
| Net Cash | 93.81M |
| Net Cash Per Share | $9.99 |
| Equity (Book Value) | 138.96M |
| Book Value Per Share | 14.80 |
| Working Capital | 108.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$62.64 million and capital expenditures -$12.41 million, giving a free cash flow of -$75.05 million.
| Operating Cash Flow | -62.64M |
| Capital Expenditures | -12.41M |
| Free Cash Flow | -75.05M |
| FCF Per Share | -$7.99 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,980.44% |
| Pretax Margin | -1,810.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -167.19% |
| Shareholder Yield | -167.19% |
| Earnings Yield | -58.73% |
| FCF Yield | -50.42% |
Analyst Forecast
The average price target for Korro Bio is $85.67, which is 440.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $85.67 |
| Price Target Difference | 440.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 123.56% |
| EPS Growth Forecast (5Y) | -6.23% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of 1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1 |
| Piotroski F-Score | 1 |